Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KRT19

KRT19

Basics

Aliases:
This biomarker is also known as:
  • keratin, type I cytoskeletal 19,
  • keratin, type I, 40-kd,
  • Keratin-19,
  • cytokeratin 19,
  • 40-kDa keratin intermediate filament,
  • Cytokeratin 19,
  • K1CS,
  • CK19,
  • MGC15366,
  • keratin 19,
  • K19,
  • Cytokeratin-19,
  • CK-19,

View in BioMuta

Description…

KRT19, a member of the keratin family which exists as a heterotetramer of two type I and two type II keratins, is involved in the organization of myofibers. Together with KRT8, KRT19 helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. KRT18 is expressed in a defined zone of basal keratinocytes in the deep outer root sheath of hair follicles. It is also observed in sweat gland and mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, ectocervical epithelium (at protein level). It is expressed in epidermal basal cells and in nipple epidermis. It is also evident in a subset of vascular wall cells in both the veins and artery of human umbilical cord, and in umbilical cord vascular smooth muscle, as well as in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma in structures that contain dystrophin and spectrin.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: KRT19

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Curated

Overview

KRT19 (keratin 19) has been shown to be a helpful biomarker in differentiating procarcinoma from squamous cell carcinoma when screened as part of a panel including keratin 7 (KRT7), keratin 19 and nestin (NES). An assay composed of KRT19, KRT8, and KRT18 has been used to detect, measure, and evaluate circulating tumor cells (CTCs) in the blood of healthy and metastatic patients.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.